Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Latest full-year results from official filings.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
No adverse media involving Huma found in HSH's search of the last 24 months. May 2025: Huma acquired US respiratory monitoring company Aluna and announced a growth partnership with Eckuity Capital; terms were not disclosed.
Data breaches, cyber incidents, regulator action and assurance status.
No data breaches, cyber incidents or regulator action involving Huma found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Recalls, safety notices, regulator action and clinical safety concerns.
No recalls, safety notices or warning letters involving Huma products found in HSH's search of the last 24 months.
Contract delivery, go-lives, terminations and disputes.
No significant new NHS contracts, terminations or customer disputes involving Huma found in HSH's search of the last 24 months.